title: Report on the FDA-AACR Immuno-oncology Drug Development Workshop.
abstract: The FDA-AACR Immuno-oncology Drug Development Workshop was held in Washington, DC, from October 13 to 14, 2016. This interdisciplinary forum included government, industry, and academic leaders in pharmacology and oncology. The aim of the meeting was to discuss methodologies in nonclinical and clinical research, safety monitoring, efficacy endpoints, and statistical evaluation of cancer immunotherapy products. This summary highlights topics and viewpoints raised by the presenters and discussants and should not be viewed as the conclusions or recommendations of the workshop as a whole.Cancer Immunol Res; 5(4); 282-5. ©2017 AACR.
authors.affiliation: Critical Care Medicine Department, Clinical Center, NIH, Bethesda, Maryland.
authors.forename: Colleen
authors.initials: C
authors.lastname: Curran
authors.affiliation: Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland. sharone@mail.nih.gov.
authors.forename: Elad
authors.initials: E
authors.lastname: Sharon
mesh_terms: D000818:Animals; D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000074322:Antineoplastic Agents, Immunological; D014408:Biomarkers, Tumor